Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Stephens & Co. Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $135

Author: Benzinga Newsdesk | June 03, 2025 06:11am
Stephens & Co. analyst Sudan Loganathan downgrades Blueprint Medicines (NASDAQ:BPMC) from Overweight to Equal-Weight and lowers the price target from $150 to $135.

Posted In: BPMC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist